Cargando…

Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors

SIMPLE SUMMARY: Deficient Mismatch Repair (dMMR) is an oncogenic path accounting for around 15% of cancers. It is considered as the first predictive marker of efficacy for immune checkpoint inhibitors (ICI). However, around 39% of cases are refractory and additional biomarkers are needed. The Lung I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Auclin, Edouard, Vuagnat, Perrine, Smolenschi, Cristina, Taieb, Julien, Adeva, Jorge, Nebot-Bral, Laetitia, Garcia de Herreros, Marta, Vidal Tocino, Rosario, Longo-Muñoz, Federico, El Dakdouki, Yola, Martín-Romano, Patricia, Gaba, Lydia, Saurí, Tamara, Oliveres, Helena, Castañón, Eduardo, Garcia-Carbonero, Rocio, Besse, Benjamin, Massard, Christophe, Mezquita, Laura, Hollebecque, Antoine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345164/ https://www.ncbi.nlm.nih.gov/pubmed/34359675 http://dx.doi.org/10.3390/cancers13153776

Ejemplares similares

Predicting immunotherapy outcomes in patients with MSI tumors using NLR and CT global tumor volume
por: Belkouchi, Younes, et al.
Publicado: (2022)

Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score
por: Pierro, Monica, et al.
Publicado: (2022)

Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers
por: Nebot-Bral, Laetitia, et al.
Publicado: (2022)

Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176
por: Auclin, Edouard, et al.
Publicado: (2021)

Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential
por: Baldini, Capucine, et al.
Publicado: (2019)

Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types
por: Martin‐Romano, Patricia, et al.
Publicado: (2020)

Radon and Lung Cancer: Current Trends and Future Perspectives
por: Riudavets, Mariona, et al.
Publicado: (2022)

Efficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice. An AGEO study
por: Alouani, E., et al.
Publicado: (2023)

Immunotherapy in Advanced Biliary Tract Cancers
por: Boilève, Alice, et al.
Publicado: (2021)

Integrin-α(V)-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade
por: Malenica, Ines, et al.
Publicado: (2021)

CD103(+)CD8(+) T(RM) Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17
por: Corgnac, Stéphanie, et al.
Publicado: (2020)

Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer
por: Geraud, Arthur, et al.
Publicado: (2020)

Molecular targeted therapy of BRAF-mutant colorectal cancer
por: Ducreux, Michel, et al.
Publicado: (2019)

Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer
por: Duchemann, Boris, et al.
Publicado: (2020)

1714P Change of circulating pro-inflammatory markers between pre-COVID-19 condition and COVID-19 diagnosis predicts early death in cancer patients: The FLARE score
por: Seguí, E., et al.
Publicado: (2020)

Immunotherapy and Hepatocellular Cancer: Where Are We Now?
por: Valery, Marine, et al.
Publicado: (2022)

Prolonged Survival in a Patient with a Pancreatic Acinar Cell Carcinoma
por: Ploquin, Anne, et al.
Publicado: (2015)

P09.15 Severity of Lung Cancer Disease in Hospitalized Patients During COVID-19
por: Fernández-Mañas, L., et al.
Publicado: (2021)

Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments
por: Valery, Marine, et al.
Publicado: (2023)

CD8(+)PD-1(+) to CD4(+)PD-1(+) ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers
por: Duchemann, Boris, et al.
Publicado: (2022)

Pembrolizumab in Asian patients with microsatellite‐instability‐high/mismatch‐repair‐deficient colorectal cancer
por: Yoshino, Takayuki, et al.
Publicado: (2022)

Precision Medicine in Pancreatic Ductal Adenocarcinoma: The Impact of Targeted Therapies on Survival of Patients Harboring Actionable Mutations
por: Tarabay, Anthony, et al.
Publicado: (2023)

Prognostic factors of toxicity of immune checkpoint inhibitors in nonsmall cell lung cancer and small cell lung cancer patients: The ToxImmune study
por: Difoum, Francoise, et al.
Publicado: (2022)

Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer
por: Cartry, Jérôme, et al.
Publicado: (2023)

Spontaneous Primary Intraventricular Hemorrhage: Clinical Features and Early Outcome
por: Arboix, Adrià, et al.
Publicado: (2012)

Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer
por: Park, Wungki, et al.
Publicado: (2019)

Unilateral Keratoconus after Chronic Eye Rubbing by the Nondominant Hand
por: Bral, Nathalie, et al.
Publicado: (2017)

1681P First results of the COCO study: COVID-19 outcomes in patients with cancer
por: Seguí, E., et al.
Publicado: (2020)

A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials
por: Kempf, Emmanuelle, et al.
Publicado: (2016)

1617P Sustained cancer clinical trial activity during the COVID-19 pandemic
por: Bayle, A., et al.
Publicado: (2021)

P09.28 Access to Intermediate and Intensive Care for Patients With Lung Cancer During the COVID-19 Period
por: Gorría, T., et al.
Publicado: (2021)

Infarctions in the vascular territory of the posterior cerebral artery: clinical features in 232 patients
por: Arboix, Adrià, et al.
Publicado: (2011)

Infarction in the territory of the anterior cerebral artery: clinical study of 51 patients
por: Arboix, Adrià, et al.
Publicado: (2009)

Pretreatment with statins improves early outcome in patients with first-ever ischaemic stroke: a pleiotropic effect of statins or a beneficial effect of hypercholesterolemia?
por: Arboix, Adrià, et al.
Publicado: (2010)

Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma
por: Parent, Pauline, et al.
Publicado: (2023)

Patient-reported tolerability of adverse events in phase 1 trials
por: Henon, Clémence, et al.
Publicado: (2017)

Mismatch Mania.
Publicado: (1995)

Mismatch Measurements
por: Arduini, Gianluigi
Publicado: (1999)

Evolutionary mismatch
por: Manus, Melissa B
Publicado: (2018)

Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic
por: Bayle, Arnaud, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9bf8nam0o6g9jkbd331j20h059